Model Medicines Showcased MDL-001’s Pan-Hepatic Potential at HEP-DART 2025
Events
Patrick ONeill
Model Medicines presented preclinical MDL-001 data at HEP-DART 2025, where Virgil Woods Jr., Ph.D., shared results supporting the candidate’s potential across HCV, HBV, HDV, and key hepatic co-infection models.
Patrick ONeill
Head of Partnerships and Investor Relations
BioSpace covered Model Medicines’ presentation of preclinical data for MDL-001 at HEP-DART 2025, a leading conference focused on new therapeutics for chronic hepatitis and viral liver disease. Presented by Virgil Woods Jr., Ph.D., the data highlighted MDL-001’s activity across HCV, HBV, and HDV, including HCV/HBV and HDV/HBV co-infection models, as well as its reported equivalence to sofosbuvir in HCV.
The moment was especially notable given HEP-DART’s 30th anniversary and the presence of Raymond Schinazi, Ph.D., a world-renowned antiviral drug discovery pioneer and founder of the DART conference series, who is pictured with Dr. Woods in the event photo. Together, the setting and presentation underscored MDL-001’s potential relevance to the future of viral liver disease treatment and broader hepatitis elimination efforts.
